PRESS RELEASES

JANUARY 15, 2009
APT Pharmaceuticals Adds Stephen Aselage to Board of Directors

SEPTEMBER 30, 2008
APT Pharmaceuticals Secures $32 Million in Series B Financing

DECEMBER 3, 2007
APT Pharmaceuticals Adds Paul Sekhri to Board of Directors

NOVEMBER 19, 2007
APT Pharmaceuticals Expands Management Team

OCTOBER 4, 2007
APT Pharmaceuticals Closes New $22 Million Funding Round

JUNE 5, 2007
APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection

SEPTEMBER 6, 2006
Former Chiron Executive Joins APT Pharmaceuticals as CEO

MARCH 21, 2006
APT Pharmaceuticals Adds Vivo Ventures in Final Close of $9 Million First Round

MEDIA COVERAGE

PALO ALTO /KGO ABC7 NEWS – JULY 8, 2008
APT supports Team Northern California at USA Transplant Games

START-UP MAGAZINE – MAY 2008
APT profiled in Start-Up Magazine

SILICON VALLEY / SAN JOSE BUSINESS JOURNAL– NOVEMBER 2, 2007
APT Moves Are Closely Followed

DOWJONES VENTUREWIRE– OCTOBER 5, 2007
Specialty Drug Co. APT Pharma Breathes In $22M

BIOWORLD TODAY– OCTOBER 5, 2007
APT Targeting Lung Transplant, Disease With $22M Financing

SAN FRANCISCO BUSINESS TIMES – JUNE 15, 2007
Chiron Refugees Adopt 'Orphans' from Novartis

BURLINGAME, CA – OCTOBER 4, 2007

APT Pharmaceuticals Closes
New $22 Million Funding Round

APT Pharmaceuticals, a specialty drug development company focused on effective treatments for significant unmet medical needs, announced today that it has closed a $22 million Series A-2 round of financing. New investors Versant Ventures and Great Point Partners joined existing firms Vivo Ventures and Charter Life Sciences in the round. Coinciding with the funding, Camille Samuels, Managing Director, Versant Ventures and David Kroin, Managing Director, Great Point Partners have joined the APT board.

The company, which has received a total of $30 million in funding to date, will use the new funding to advance its development pipeline which includes Pulminiq, a Phase III drug for prevention of lung transplant rejection, a novel cardioprotectant and several other projects.

APT also announced the appointment of Ralph Niven PhD, as Chief Technology Officer. Dr. Niven has two decades of experience in the operations, management and technology development of biopharmaceutical companies and has worked extensively in all aspects of preclinical and early clinical development. He was formerly Senior Vice President of Preclinical Development for Discovery Labs.

"APT has all the makings of a premier drug development firm with its experienced and respected team and their keen sense for clinical unmet needs that address sound market segments," said Camille Samuels of Versant Ventures. “Also, APT has a strong, capital-efficient business model encompassing a robust therapeutic drug development strategy,” added Samuels.

“We are extremely pleased with the outcome of this funding round,” said Dr. Stephen Dilly, President and CEO of APT. “We have added two more high-caliber investors to our investor base and secured the resources to make major progress with our development pipeline. I am very excited to welcome Camille and David onto our Board and to have Ralph join our senior executive team. We now have the people, the products and the resources we need to build significant value over the next few years.”

About APT Pharmaceuticals, Inc.

APT Pharmaceuticals, Inc. is a drug development company based in Burlingame, California. APT is backed by several leading venture capital firms, including Vivo Ventures, Versant Ventures and Charter Life Sciences and by Great Point Partners, a leading healthcare investment firm. For more information, please visit www.aptbio.com.

Media Contacts

Lisa Kelaita
New Venture Communications
lkelaita@newventurecom.com
(650) 343-2735

Ted Rossman
New Venture Communications
trossman@newventurecom.com
(914) 432-7083